IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control these conditions. Participants receive the drug every 4 weeks for at least…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated May 26, 2026 08:38 UTC
-
New drug shows promise in slowing rare kidney disease
Disease control OngoingThis study tests a new drug called sparsentan against a standard treatment for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 400 adults with the condition took either sparsentan or a standard blood pressure medication for about two years. Th…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New hope for kidney disease: phase 3 trial targets protein leak
Disease control OngoingThis study tests an investigational drug called povetacicept in adults with IgA nephropathy, a kidney disease that can lead to kidney failure. About 605 participants will receive either the drug or a placebo to see if it reduces protein in the urine and preserves kidney function …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated May 26, 2026 08:27 UTC
-
New hope for kidney disease: experimental drug aims to slow damage in IgA nephropathy
Disease control OngoingThis study tests an experimental drug called BION-1301 in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can slow the loss of kidney function and reduce protein in the urine over two years. Participants receive ei…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug shows promise in slowing rare kidney disease
Disease control OngoingThis phase 3 trial tests a drug called sibeprenlimab for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 530 adults are receiving either the drug or a placebo to see if it reduces protein in urine and slows kidney function decline. The goal is…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug shows promise in slowing kidney disease for IgA patients
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of sibeprenlimab, an experimental drug, in about 600 adults with IgA nephropathy—a kidney disease that can lead to kidney failure. Participants must have completed a prior sibeprenlimab study and may benefit from continued t…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2, PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC